A Phase 1 interventional study of Dasatinib and Dasatinib in Leukemia, sponsored by Bristol-Myers Squibb. Completed at 13 sites in 6 countries. Open to participants aged 12 Months to 20 Years. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
The purpose of this clinical research study was to establish a recommended phase 2 once daily (QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous treatment) leukemia in children and adolescents. The side effects that this oral investigational drug may have in children, and the levels of the drug in the blood, will be studied at different doses.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 63 is above the median of 38 across 4,247 interventional studies indexed under Leukemia.
Browse Leukemia studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
Drug: Dasatinib
Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
Drug: Dasatinib
Participants with second or subsequent relapse of Ph- ALL or Ph- AML
Drug: Dasatinib
Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained. Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT).
Also known as: Sprycel, BMS-354825
Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained. Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
Also known as: Sprycel, BMS-354825
Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained. Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
Also known as: Sprycel, BMS-354825
Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
The recommended phase 2 dasatinib dose was determined based on efficacy, safety, and pharmacokinetic data obtained at the prespecified dose levels.
Time frame: From the date of first dose to end-of-treatment (EOT) (Median duration of therapy in months: Stratum 1=24.11 [Range:2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0.
AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade 3 = Severe; Grade 4 = Life-threatening or disabling.
Time frame: From the date of first dose until at least 30 days after the last dose of study drug (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Dose-limiting Toxicity (DLT)
DLTs: AEs which were at least possibly drug-related occurring within first 3 weeks of dasatinib therapy (toxicities occurring after 21 days were also considered) and are:- --Any nonhematologic clinically-apparent toxicity of Grade(GR)≥3 occurring despite appropriate medical management and GR4 laboratory abnormality/GR3 lasting ≥7 days --GR4 neutropenia or thrombocytopenia lasting ≥7 days and not explained by the presence of leukemia after hematopoietic reconstitution --Any clinically important toxicity of GR≥2 requiring treatment discontinuation or interruption ≥7 days.
Time frame: From the date of first dose until at least 30 days after the last dose of study drug (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Hematology Abnormalities by NCI CTCAE Version 3.0
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. WBC: GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3=\<2.0-1.0\*10\^9/L; GR4=\<1.0\*10\^9/L. ANC: GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3=\<1.0-0.5\*10\^9/L; GR4=\<0.5\*10\^9/L. Hemoglobin: GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3=\<8.0-6.5g/dL; GR4=\<6.5g/dL. Platelets: GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3=\<50.0-25.0\*10\^9/L; GR4=\<25.0\*10\^9/L.
Time frame: Days 8, 15, 22, 29, 36, 43, then every 3 weeks, then every 3 months after 1 Year, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Serum Chemistry Abnormalities (Calcium, Magnesium, and Phosphate) by NCI CTCAE Version 3.0
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Low calcium: GR1=\<LLN-8.0 mg/dL, GR2=\<8.0-7.0 mg/dL, GR3=\<7.0-6.0 mg/dL, GR4=\<6.0 mg/dL; Low magnesium: GR1=\<LLN-1.2 mg/dL, GR2=\<1.2-0.9 mg/dL, GR3=\<0.9-0.7 mg/dL, GR4=\<0.7 mg/dL; Low phosphate: GR1=\<LLN - 2.5 mg/dL, GR2=\<2.5 - 2.0 mg/dL, GR3=\<2.0 - 1.0 mg/dL, GR4=\<1.0 mg/dL.
Time frame: Days 22 and 43, then every 12 weeks, then every 24 weeks after 24 months of treatment, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) by NCI CTCAE Version 3.0
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. AST and ALT: GR1=\>ULN-2.5\*ULN; GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4:\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN.
Time frame: Days 22 and 43, then every 12 weeks, then every 24 weeks after 24 months of treatment, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Major Cytogenetic Response (MCyR) at Any Time in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)
Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that is either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM.
Time frame: Strata 1 and 2/3: At Week 7, 13, then every 12 weeks, and EOT; Stratum 2/3: Additionally at Week 4, 19, 31 (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])
Number of Participants With Major Cytogenetic Response (MCyR) in Stratum 1 (Ph+ CP-CML) Within First 12 and 24 Weeks
Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM.
Time frame: After completion of Week 12 and 24 (measured at Weeks 13 and 25)
Best Cytogenetic Response (CyR) in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)
Best CyR was assessed based on the percentages of Ph+ metaphases of ≥20 analyzed metaphases in BM sample. Participants with complete, partial, minor, minimal, or no CyR. Refer to Outcome Measure 7 for definitions of CCyR and PCyR. Minor CyR:\>35%-65% Ph+ cells in metaphase in BM. Minimal CyR:\>65%-95% Ph+ cells in metaphase in BM. No CyR:\>95%-100% Ph+ cells in metaphase in BM. Unable to determine:Participants without valid cytogenetic assessment (i.e., at least 1 metaphase observed and number of Ph+ metaphases smaller than total number of metaphases \[%Ph+ \<100%\]).
Time frame: Strata 1 and 2/3: At Weeks 7, 13, then every 12 weeks, and EOT; Stratum 2/3: Additionally at Weeks 4, 19, 25, 31 (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])
Percentage of Participants With Complete Cytogenetic Response (CCyR) or Major Cytogenetic Response (MCyR) at Recommended Phase II Dose
Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM.
Time frame: Strata 1 and 2/3: At Week 7, 13, then every 12 weeks, and EOT; Stratum 2/3: Additionally at Week 4, 19, 31 (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])
Time to Major Cytogenetic Response (MCyR) in Responders: Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)
Defined as time (in days) from the first dose of dasatinib until criteria were first met for MCyR. MCyR: A CyR that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM. The Kaplan-Meier plot was used. A 2-sided, 95% confidence interval (CI) for the median was computed using the Brookmeyer and Crowley method.
Time frame: Strata 1 and 2/3: At Weeks 7, 13, 25, 37, then every 12 weeks; Stratum 2/3: Additionally at Weeks 4, 19, 31; until first MCyR (maximum participant time to first MCyR of 92 days).
Duration of Major Cytogenetic Response (MCyR) in Responders (Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML])
Defined as the time (in months) from the first day that all criteria were met for MCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best responses were MCyR and CCyR respectively). MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
Time frame: From the date of first MCyR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 48.6 months)
Duration of Complete Cytogenetic Response (CCyR) in Responders: Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML]
Defined as time (in months) from the first day that all criteria were met for CCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best response was CCyR). CCyR = 0% Ph+ metaphases of ≥ 20 analyzed metaphases in BM aspiration. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
Time frame: From the date of first CCyR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 45.1 months)
Number of Participants With Major Hematologic Response (MaHR) at Any Time in Stratum 2/3 (Ph+ ALL or AP/BP-CML) and Stratum 4 (Ph- ALL/AML)
Defined as participants having as best response complete hematologic response (CHR) or CHR with incomplete platelet recovery (CHRp). Criteria: CHR-WBC in Peripheral Blood (PB):≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm\^3 and ≤450,000/mm\^3; ANC:≥ 1000/mm\^3; Blasts in BM:\<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) \& ANC:20,000/mm\^3 ≤platelet \<100,000/mm\^3 \& /or 500/mm\^3 ≤ANC ≤1000/mm\^3.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; at Week 10 (only stratum 4); then every 12 weeks upto 24 months; then once/year; EOT(Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Major Hematologic Response (MaHR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML) Within First 6 and 24 Weeks
Defined as participants having as best response a CHR or CHRp. Criteria: CHR-WBC in PB:≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm\^3 and ≤450,000/mm\^3; ANC:≥ 1000/mm\^3; Blasts in BM:\<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) and ANC:20,000/mm\^3 ≤platelet \<100,000/mm\^3 and /or 500/mm\^3 ≤ANC ≤1000/mm\^3.
Time frame: After completion of Week 6 and 24 (measured at weeks 7 and 25)
Best Hematologic Response (HR) At Any Time: Stratum 1 (Ph+ CP-CML)
HR: Determined by complete blood count (CBC), differential, and platelet count (PLT). Criteria for complete hematologic response (CHR): WBC in PB: \<10,000/mm\^3; Immature cells in PB: No blasts or promyelocytes (myelocytes + metamyelocytes) \<5%; Basophils in PB: \<5%; Platelet count (untransfused): \<450,000/mm\^3; Extra medullary disease: No extramedullary leukemia, including no splenomegaly. Unconfirmed HR = All criteria met. Confirmed HR = Criteria for HR fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])
Best Hematologic Response (HR) At Any Time: Stratum 2/3 (Ph+ ALL or AP/BP-CML)
HR was determined by CBC, differential, and platelet count. Refer to outcome measure 15 for criteria for CHR and CHRp. Criteria for minor hematologic response (MiHR): CHRp except blasts in BM-≥5% and ≤15% blasts in BM. Unconfirmed HR = All criteria met. periph=peripheral. Confirmed HR = Criteria for HR fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; then every 12 weeks up to 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72])
Best Hematologic Response (HR) At Any Time: Stratum 4 (Ph- ALL/AML)
HR was determined by CBC, differential, and platelet count. Unable to determine = Participants without any valid hematologic assessments.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 10, 13, 19, 25, 31, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 4=1.14 [Range: 0.03-3.38])
Time to Major Hematologic Response (MaHR): Stratum 2/3 (PH+ ALL or AP/BP-CML)
Defined as time (in days) from first dose of dasatinib until the first day MaHR criteria were met, provided they were confirmed later (after 28 days) with no concomitant use of anagrelide or hydroxyurea during this interval. MaHR: Defined as participants having as best response a CHR or CHRp. Refer to Outcome Measure 15 for criteria for CHR and CHRp. Estimated by the Kaplan-Meier method and a 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; then every 12 weeks upto 24 months; then once/year; until confirmed MaHR (maximum participant time to first MaHR of 44 days).
Time to Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)
Time to CHR is the time (in days) from first dose of dasatinib until the first day CHR criteria were met, provided they were confirmed later after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval. Refer to Outcome Measure 16 for criteria to CHR in Stratum 1 and to Outcome Measure 15 for criteria for CHR in Stratum 2/3. Estimated by the Kaplan-Meier method and a 2-sided 95% CI for median was computed using the Brookmeyer and Crowley method.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; at Week 4, 19, 31 (only stratum 2/3); then every 12 weeks upto 24 months; then once/year; until criteria was first met for CHR (maximum participant time to first CHR of 65 days).
Duration of Major Hematologic Response (MaHR): Stratum 2/3 (Ph+ALL or AP/BP-CML)
Duration of MaHR is the time (in months) from the first day criteria were met for MaHR, provided they were confirmed later at least after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval, until death or progression was first observed. MaHR: Defined as participants having as best response a CHR or CHRp. Refer to outcome measure 20 for criteria for CHR or CHRp. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
Time frame: From the date of first confirmed MaHR to date of progression, death, or last tumor assessment (maximum participant duration of response of 37 months).
Duration of Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)
Duration of CHR is the time (in months) from the first day criteria were met for CHR, provided they were confirmed later (after 28 days) with no concomitant use of anagrelide or hydroxyurea during this interval until death or progression was first observed. Refer to Outcome Measure 20 for criteria for CHR (Stratum 1) and Outcome Measure 19 for CHR (Stratum 2/3). The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
Time frame: From the date of first confirmed CHR to date of progression, death, or last tumor assessment (maximum participant duration of response of 50 months).
Percentage of Participants With Confirmed Hematologic Response (HR) at Recommended Phase II Dose: Stratum 1 (Ph+ CP-CML)
A participant was said to have a confirmed HR if all the criteria for HR were fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. HR observed in stratum 1 was CHR. Refer to Outcome Measure 20 for criteria for CHR. The Clopper and Pearson method was used to compute 95% exact CIs.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])
Percentage of Participants With Confirmed Hematologic Response (HR) at Recommended Phase II Dose: Stratum 2/3 (Ph+ALL or AP/BP-CML)
A participant is said to have a confirmed HR if criteria for HR were fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. Confirmed HR observed in stratum 2/3 was either CHR or MaHR or overall hematologic response (OHR). Refer to Outcome Measure 19 for criteria for CHR and MaHR. OHR is defined as MaHR or MiHR. MiHR=CHRp except blasts in BM (≥ 5% and ≤ 15% blasts in BM). The Clopper and Pearson method was used to compute 95% exact CIs.
Time frame: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72])
Number of Participants With Molecular Responses in Stratum 1 (Ph+ CP-CML)
Molecular response was calculated by measuring p210 variant of BCR-ABL transcripts in blood during treatment using quantitative polymerase chain reaction (qPCR) assay. Major molecular response (MMR): Ratio of the BCR-ABL to ABL \<10\^-3 or 0.1% on the international scale. Complete molecular response (CMR): Complete absence of BCR-ABL or the ratio is \<10\^-4.5 or 0.00316% on the international scale. Confirmed MMR or CMR = Criteria met again \>6 weeks. BCR-ABL=the fused gene found in participants with this type of CML.
Time frame: At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])
Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML)
Molecular response was calculated by measuring BCR-ABL transcripts in blood during treatment using qPCR assay. MMR: Ratio of the BCR-ABL to ABL \<10\^-3 or a ≥3 log reduction from baseline in participants with p190 variant; ratio of the BCR-ABL to ABL \<10\^-3 on the international scale in participants with p210 variant. BCR-ABL=the fused gene found in participants with this type of CML.
Time frame: At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72])
Progression Free Survival (PFS)
Time in months from 1st first dose until progression (resistance or refractory disease) or death was first documented by investigator. Progressive disease: Resistant disease for which investigator may electively stop treatment or refractory disease requiring cessation of study treatment. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley.
Time frame: From the date of randomization to date of progression, death, last tumor assessment, or 5 years after EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Overall Survival (OS)
Defined as time in months from start of study therapy to death. The OS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median OS time was computed using the Brookmeyer and Crowley method.
Time frame: From start of study therapy until death or 5 years after EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])
Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) by Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Observed Maximum Plasma Concentration (Cmax) by Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Dose Normalized Cmax is the maximum observed concentration of drug substance in plasma normalized for different dasatinib dose levels.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-T\] is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, normalized by dasatinib dose level.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time, normalized by dasatinib dose level.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Observed Maximum Plasma Concentration (Cmax) by Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(INF) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Observed Maximum Plasma Concentration (Cmax) by Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration.
Time frame: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).
Concentration of Dasatinib in Cerebrospinal Fluid (CSF) by Dose Level and Age Group
Concentration of dasatinib in CSF was assessed only in participants who had lumbar puncture during the treatment. y=years
Time frame: 4 hours after oral dose
Number of Participants With BCR-ABL Mutations at Baseline: Stratum1 Ph+ CP-CML and Stratum 2/3 Ph+ALL or AP/BP-CML
BCR-ABL, also referred to as the Philadelphia chromosome, is formed from the fusion of the BCR gene on chromosome 22 with the ABL gene on chromosome 9.
Time frame: At baseline (within 3 weeks before initiation of study therapy)
Number of Participants With BCR-ABL Mutations at End-of-Treatment: Stratum1 Ph+ CP-CML and Stratum2/3 Ph+ ALL or AP/BP-CML
BCR-ABL = These are fused genes found in participants with this type of leukemia.
Time frame: At EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])
Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at Baseline
FLT3 and KIT = These are fused genes found in participants with this type of leukemia.
Time frame: At baseline (within 3 weeks before initiation of study therapy)
Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at End-Of-Treatment
FLT3 and KIT = These are fused genes found in participants with this type of leukemia.
Time frame: At EOT (Median duration of therapy in months: Stratum 4=1.14 [Range: 0.03-3.38])
Number of Participants With Hematologic Toxicity at Baseline by NCI CTCAE Version 3.0
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. White Blood Cell (WBC):GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3=\<2.0-1.0\*10\^9/L; GR4=\<1.0\*10\^9/L. Absolute Neutrophil Count (ANC): GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3=\<1.0-0.5\*10\^9/L; GR4=\<0.5\*10\^9/L. Hemoglobin: GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3=\<8.0-6.5g/dL; GR4=\<6.5g/dL. Platelets: GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3=\<50.0-25.0\*10\^9/L; GR4=\<25.0\*10\^9/L. LLN=lower limit of normal.
Time frame: At baseline (within 1 week before initiation of study therapy)
Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) at Baseline by NCI CTCAE Version 3.0
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Aspartate aminotransferase (AST) and alanine aminotransferase(ALT): GR1=\>ULN-2.5\*ULN; GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4=\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN. ULN=upper limit of normal.
Time frame: At baseline (within 1 week before initiation of study therapy)
Number of Participants With Serum Chemistry Abnormalities (Calcium, Magnesium, and Phosphate) at Baseline by NCI CTCAE Version 3.0
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Low calcium: GR1=\<LLN-8.0 mg/dL, GR2=\<8.0-7.0 mg/dL, GR3=\<7.0-6.0 mg/dL, GR4=\<6.0 mg/dL; Low magnesium: GR1=\<LLN-1.2 mg/dL, GR2=\<1.2-0.9 mg/dL, GR3=\<0.9-0.7 mg/dL, GR4=\<0.7 mg/dL; Low phosphate: GR1=\<LLN - 2.5 mg/dL, GR2=\<2.5 - 2.0 mg/dL, GR3=\<2.0 - 1.0 mg/dL, GR4=\<1.0 mg/dL.
Time frame: At baseline (within 1 week before initiation of study therapy)
| Milestone | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| Started | 17 | 17 | 24 |
| Completed | 17 | 17 | 24 |
| Not completed | 0 | 0 | 0 |
The recommended phase 2 dasatinib dose was determined based on efficacy, safety, and pharmacokinetic data obtained at the prespecified dose levels.
| mg/m^2 QD | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | 60 | 80 | NA |
AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade 3 = Severe; Grade 4 = Life-threatening or disabling.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|---|---|---|---|
| Drug-Related Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Drug-Related SAEs | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 2 |
| Drug-Related AEs Leading to Discontinuation | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Grade 3/4 AEs | 5 | 3 | 4 | 3 | 3 | 4 | 3 | 2 |
DLTs: AEs which were at least possibly drug-related occurring within first 3 weeks of dasatinib therapy (toxicities occurring after 21 days were also considered) and are:- --Any nonhematologic clinically-apparent toxicity of Grade(GR)≥3 occurring despite appropriate medical management and GR4 laboratory abnormality/GR3 lasting ≥7 days --GR4 neutropenia or thrombocytopenia lasting ≥7 days and not explained by the presence of leukemia after hematopoietic reconstitution --Any clinically important toxicity of GR≥2 requiring treatment discontinuation or interruption ≥7 days.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. WBC: GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3=\<2.0-1.0\*10\^9/L; GR4=\<1.0\*10\^9/L. ANC: GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3=\<1.0-0.5\*10\^9/L; GR4=\<0.5\*10\^9/L. Hemoglobin: GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3=\<8.0-6.5g/dL; GR4=\<6.5g/dL. Platelets: GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3=\<50.0-25.0\*10\^9/L; GR4=\<25.0\*10\^9/L.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|---|---|---|---|
| WBC GR1 | 6 | 4 | 2 | 1 | 1 | 1 | 0 | 0 |
| WBC GR2 | 0 | 1 | 3 | 3 | 0 | 1 | 1 | 1 |
| WBC GR3 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 |
| WBC GR4 | 0 | 0 | 1 | 3 | 2 | 2 | 3 | 1 |
| ANC GR1 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| ANC GR2 | 4 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| ANC GR3 | 1 | 2 | 2 | 0 | 0 | 2 | 0 | 2 |
| ANC GR4 | 0 | 1 | 3 | 4 | 4 | 4 | 6 | 3 |
| Platelet GR1 | 4 | 4 | 0 | 2 | 0 | 0 | 0 | 0 |
| Platelet GR2 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 |
| Platelet GR3 | 2 | 0 | 4 | 1 | 0 | 1 | 1 | 1 |
| Platelet GR4 | 0 | 0 | 4 | 3 | 4 | 5 | 5 | 5 |
| Hemoglobin GR1 | 3 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin GR2 | 4 | 1 | 5 | 3 | 2 | 3 | 3 | 3 |
| Hemoglobin GR3 | 0 | 0 | 1 | 4 | 3 | 1 | 3 | 2 |
| Hemoglobin GR4 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Low calcium: GR1=\<LLN-8.0 mg/dL, GR2=\<8.0-7.0 mg/dL, GR3=\<7.0-6.0 mg/dL, GR4=\<6.0 mg/dL; Low magnesium: GR1=\<LLN-1.2 mg/dL, GR2=\<1.2-0.9 mg/dL, GR3=\<0.9-0.7 mg/dL, GR4=\<0.7 mg/dL; Low phosphate: GR1=\<LLN - 2.5 mg/dL, GR2=\<2.5 - 2.0 mg/dL, GR3=\<2.0 - 1.0 mg/dL, GR4=\<1.0 mg/dL.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|---|---|---|---|
| Low Calcium GR1 | 3 | 0 | 2 | 2 | 2 | 0 | 1 | 0 |
| Low Calcium GR2 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | 1 |
| Low Calcium GR3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Low Calcium GR4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Low magnesium GR1 | 1 | 1 | 5 | 0 | 1 | 0 | 4 | 1 |
| Low Magnesium GR2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Low Magnesium GR3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Low Magnesium GR4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Low Phosphate GR1 | 2 | 1 | 2 | 2 | 0 | 2 | 2 | 1 |
| Low Phosphate GR2 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 |
| Low Phosphate GR3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Low Phosphate GR4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. AST and ALT: GR1=\>ULN-2.5\*ULN; GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4:\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|---|---|---|---|
| AST GR1 | 1 | 3 | 5 | 3 | 1 | 4 | 2 | 2 |
| AST GR2 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| AST GR3 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
| AST GR4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| High ALT GR1 | 4 | 4 | 4 | 2 | 0 | 2 | 3 | 2 |
| High ALT GR2 | 0 | 0 | 2 | 1 | 1 | 2 | 1 | 0 |
| High ALT GR3 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 1 |
| High ALT GR4 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Total Bilirubin GR1 | 2 | 0 | 1 | 1 | 0 | 1 | 2 | 0 |
| Total Bilirubin GR2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 1 |
| Total Bilirubin GR3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Bilirubin GR4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| High Serum Creatinine GR1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| High Serum Creatinine GR2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| High Serum Creatinine GR3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| High Serum Creatinine GR4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that is either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|---|---|
| Number of Participants With Major Cytogenetic Response (MCyR) at Any Time in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML) | 9 | 6 | 4 | 7 |
Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| MCyR within first 12 weeks | 6 | 2 |
| MCyR within first 24 weeks | 9 | 5 |
Best CyR was assessed based on the percentages of Ph+ metaphases of ≥20 analyzed metaphases in BM sample. Participants with complete, partial, minor, minimal, or no CyR. Refer to Outcome Measure 7 for definitions of CCyR and PCyR. Minor CyR:\>35%-65% Ph+ cells in metaphase in BM. Minimal CyR:\>65%-95% Ph+ cells in metaphase in BM. No CyR:\>95%-100% Ph+ cells in metaphase in BM. Unable to determine:Participants without valid cytogenetic assessment (i.e., at least 1 metaphase observed and number of Ph+ metaphases smaller than total number of metaphases \[%Ph+ \<100%\]).
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|---|---|
| No Response (>95% - 100%) | 1 | 0 | 0 | 1 |
| Minimal (>65% - 95%) | 0 | 0 | 0 | 0 |
| Minor (>35% - 65%) | 1 | 0 | 0 | 0 |
| Partial (>0% - 35%) | 1 | 0 | 0 | 0 |
| Complete (0%) | 8 | 6 | 4 | 8 |
| Unable to determine | 0 | 0 | 4 | 0 |
Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM.
| percentage of participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| CCyR | 72.7 (39.0 to 94.0) | 88.9 (51.8 to 99.7) |
| MCyR | 81.8 (48.2 to 97.7) | 88.9 (51.8 to 99.7) |
Defined as time (in days) from the first dose of dasatinib until criteria were first met for MCyR. MCyR: A CyR that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM. The Kaplan-Meier plot was used. A 2-sided, 95% confidence interval (CI) for the median was computed using the Brookmeyer and Crowley method.
| days | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| Time to Major Cytogenetic Response (MCyR) in Responders: Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML) | 75.0 (43.0 to 92.0) | 33.5 (22.0 to 43.0) |
Defined as the time (in months) from the first day that all criteria were met for MCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best responses were MCyR and CCyR respectively). MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \>0% to 35% Ph+ cells in metaphase in BM. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
| months | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| Duration of Major Cytogenetic Response (MCyR) in Responders (Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML]) | 52.2 (10.0 to 56.1) | 4.6 (1.2 to 17.4) |
Defined as time (in months) from the first day that all criteria were met for CCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best response was CCyR). CCyR = 0% Ph+ metaphases of ≥ 20 analyzed metaphases in BM aspiration. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
| months | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| Duration of Complete Cytogenetic Response (CCyR) in Responders: Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML] | 48.1 (10.0 to 56.1) | 4.6 (1.2 to 17.4) |
Defined as participants having as best response complete hematologic response (CHR) or CHR with incomplete platelet recovery (CHRp). Criteria: CHR-WBC in Peripheral Blood (PB):≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm\^3 and ≤450,000/mm\^3; ANC:≥ 1000/mm\^3; Blasts in BM:\<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) \& ANC:20,000/mm\^3 ≤platelet \<100,000/mm\^3 \& /or 500/mm\^3 ≤ANC ≤1000/mm\^3.
| participants | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|---|---|
| Number of Participants With Major Hematologic Response (MaHR) at Any Time in Stratum 2/3 (Ph+ ALL or AP/BP-CML) and Stratum 4 (Ph- ALL/AML) | 2 | 6 | 0 | 0 | 0 | 0 |
Defined as participants having as best response a CHR or CHRp. Criteria: CHR-WBC in PB:≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm\^3 and ≤450,000/mm\^3; ANC:≥ 1000/mm\^3; Blasts in BM:\<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) and ANC:20,000/mm\^3 ≤platelet \<100,000/mm\^3 and /or 500/mm\^3 ≤ANC ≤1000/mm\^3.
| participants | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| MaHR within first 6 weeks | 2 | 5 |
| MaHR within first 24 weeks | 2 | 6 |
HR: Determined by complete blood count (CBC), differential, and platelet count (PLT). Criteria for complete hematologic response (CHR): WBC in PB: \<10,000/mm\^3; Immature cells in PB: No blasts or promyelocytes (myelocytes + metamyelocytes) \<5%; Basophils in PB: \<5%; Platelet count (untransfused): \<450,000/mm\^3; Extra medullary disease: No extramedullary leukemia, including no splenomegaly. Unconfirmed HR = All criteria met. Confirmed HR = Criteria for HR fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| Best Confirmed HR-Complete | 10 | 6 |
| Best Confirmed HR-No Response | 1 | 0 |
| Best Unconfirmed Hematologic Response-Complete | 10 | 6 |
| Best Unconfirmed Hematologic Response-No Response | 1 | 0 |
HR was determined by CBC, differential, and platelet count. Refer to outcome measure 15 for criteria for CHR and CHRp. Criteria for minor hematologic response (MiHR): CHRp except blasts in BM-≥5% and ≤15% blasts in BM. Unconfirmed HR = All criteria met. periph=peripheral. Confirmed HR = Criteria for HR fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval.
| participants | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| Best Confirmed HR-Complete | 1 | 5 |
| Best Confirmed HR-Complete except periph. recovery | 1 | 1 |
| Best Confirmed HR-No Response | 6 | 3 |
| Best Unconfirmed HR-Complete | 3 | 7 |
| Best Unconfirmed HR-Minor | 0 | 1 |
| Best Unconfirmed HR-No Response | 5 | 1 |
HR was determined by CBC, differential, and platelet count. Unable to determine = Participants without any valid hematologic assessments.
| participants | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) |
|---|---|---|---|---|
| Best Confirmed HR-No Response | 5 | 6 | 6 | 6 |
| Best Confirmed HR-Unable to Determine | 1 | 0 | 0 | 0 |
| Best Unconfirmed HR-No Response | 5 | 6 | 6 | 6 |
| Best Unconfirmed HR-Unable to Determine | 1 | 0 | 0 | 0 |
Defined as time (in days) from first dose of dasatinib until the first day MaHR criteria were met, provided they were confirmed later (after 28 days) with no concomitant use of anagrelide or hydroxyurea during this interval. MaHR: Defined as participants having as best response a CHR or CHRp. Refer to Outcome Measure 15 for criteria for CHR and CHRp. Estimated by the Kaplan-Meier method and a 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
| days | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|
| Time to Major Hematologic Response (MaHR): Stratum 2/3 (PH+ ALL or AP/BP-CML) | 36.0 (29.0 to 42.0) |
Time to CHR is the time (in days) from first dose of dasatinib until the first day CHR criteria were met, provided they were confirmed later after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval. Refer to Outcome Measure 16 for criteria to CHR in Stratum 1 and to Outcome Measure 15 for criteria for CHR in Stratum 2/3. Estimated by the Kaplan-Meier method and a 2-sided 95% CI for median was computed using the Brookmeyer and Crowley method.
| days | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| Time to Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML) | 21.5 (16.0 to 23.0) | 39.5 (36.0 to 44.0) |
Duration of MaHR is the time (in months) from the first day criteria were met for MaHR, provided they were confirmed later at least after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval, until death or progression was first observed. MaHR: Defined as participants having as best response a CHR or CHRp. Refer to outcome measure 20 for criteria for CHR or CHRp. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
| months | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|
| Duration of Major Hematologic Response (MaHR): Stratum 2/3 (Ph+ALL or AP/BP-CML) | 4.4 (3.5 to NA) |
Duration of CHR is the time (in months) from the first day criteria were met for CHR, provided they were confirmed later (after 28 days) with no concomitant use of anagrelide or hydroxyurea during this interval until death or progression was first observed. Refer to Outcome Measure 20 for criteria for CHR (Stratum 1) and Outcome Measure 19 for CHR (Stratum 2/3). The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method.
| months | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| Duration of Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML) | NA (14.3 to NA) | 7.3 (3.5 to NA) |
A participant was said to have a confirmed HR if all the criteria for HR were fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. HR observed in stratum 1 was CHR. Refer to Outcome Measure 20 for criteria for CHR. The Clopper and Pearson method was used to compute 95% exact CIs.
| percentage of participants | Stratum1 Ph+ CP-CML (Dasatinib 60 mg/m^2) |
|---|---|
| Percentage of Participants With Confirmed Hematologic Response (HR) at Recommended Phase II Dose: Stratum 1 (Ph+ CP-CML) | 90.9 (58.7 to 99.8) |
A participant is said to have a confirmed HR if criteria for HR were fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. Confirmed HR observed in stratum 2/3 was either CHR or MaHR or overall hematologic response (OHR). Refer to Outcome Measure 19 for criteria for CHR and MaHR. OHR is defined as MaHR or MiHR. MiHR=CHRp except blasts in BM (≥ 5% and ≤ 15% blasts in BM). The Clopper and Pearson method was used to compute 95% exact CIs.
| percentage of participants | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|
| CHR | 55.6 (21.2 to 86.3) |
| MaHR | 66.7 (29.9 to 92.5) |
| OHR | 66.7 (29.9 to 92.5) |
Molecular response was calculated by measuring p210 variant of BCR-ABL transcripts in blood during treatment using quantitative polymerase chain reaction (qPCR) assay. Major molecular response (MMR): Ratio of the BCR-ABL to ABL \<10\^-3 or 0.1% on the international scale. Complete molecular response (CMR): Complete absence of BCR-ABL or the ratio is \<10\^-4.5 or 0.00316% on the international scale. Confirmed MMR or CMR = Criteria met again \>6 weeks. BCR-ABL=the fused gene found in participants with this type of CML.
| participants | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| MMR (Overall) | 6 | 2 |
| CMR (Unconfirmed) | 3 | 1 |
| CMR (Confirmed) | 1 | 0 |
Molecular response was calculated by measuring BCR-ABL transcripts in blood during treatment using qPCR assay. MMR: Ratio of the BCR-ABL to ABL \<10\^-3 or a ≥3 log reduction from baseline in participants with p190 variant; ratio of the BCR-ABL to ABL \<10\^-3 on the international scale in participants with p210 variant. BCR-ABL=the fused gene found in participants with this type of CML.
| participants | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) |
|---|---|---|
| Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML) | 2 | 6 |
Time in months from 1st first dose until progression (resistance or refractory disease) or death was first documented by investigator. Progressive disease: Resistant disease for which investigator may electively stop treatment or refractory disease requiring cessation of study treatment. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley.
| months | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| Progression Free Survival (PFS) | 53.6 (11.4 to NA) | 4.9 (0.6 to 8.4) | 1.4 (0.4 to 1.6) |
Defined as time in months from start of study therapy to death. The OS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median OS time was computed using the Brookmeyer and Crowley method.
| months | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | 8.6 (3.2 to NA) | 3.0 (1.7 to 4.4) |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hours | Dasatinib 60 mg/m^2 QD Starting Dose |
|---|---|
| Infants and Toddlers (age<2 years old; n=2) | 0.5 ± 0.0 |
| Children (age>=2 and <12 years old; n=43) | 1.1 ± 58.6 |
| Adolescents (age>=12 and <18 years old; n=28) | 1.0 ± 82.2 |
| Above 18 Years (n=1) | 0.9 ± NA |
| Total (n=74) | 1.0 ± 70.9 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
| hours | Dasatinib 60 mg/m^2 QD Starting Dose |
|---|---|
| Infants and Toddlers (age<2 years old; n=2) | 2.1 ± 24.0 |
| Children (age>=2 and <12 years old; n=36) | 3.0 ± 62.8 |
| Adolescents (age>=12 and <18 years old; n=22) | 3.8 ± 43.9 |
| Above 18 years (n=1) | 7.3 ± NA |
| Total (n=61) | 3.3 ± 55.7 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Dose Normalized Cmax is the maximum observed concentration of drug substance in plasma normalized for different dasatinib dose levels.
| ng/mL/mg/m^2 | Dasatinib 60 mg/m^2 QD Starting Dose |
|---|---|
| Infants and Toddlers (age<2 years old; n=2) | 1.0 ± 15.2 |
| Children (age>=2 and <12 years old; n=43) | 1.9 ± 79.9 |
| Adolescents (age>=12 and <18 years old; n=28) | 1.0 ± 69.7 |
| Above 18 Years (n=1) | 0.9 ± NA |
| Total (n=74) | 1.5 ± 86.9 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-T\] is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, normalized by dasatinib dose level.
| ng.h/mL/mg/m^2 | Dasatinib 60 mg/m^2 QD Starting Dose |
|---|---|
| Infants and Toddlers (age<2 years old; n=2) | 2.8 ± 4.6 |
| Children (age>=2 and <12 years old; n=40) | 6.1 ± 95.7 |
| Adolescents (age>=12 and <18 years old; n=28) | 3.8 ± 66.8 |
| Above 18 Years (n=1) | 2.2 ± NA |
| Total (n=71) | 4.9 ± 98.1 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time, normalized by dasatinib dose level.
| ng.h/mL/mg/m^2 | Dasatinib 60 mg/m^2 QD Starting Dose |
|---|---|
| Infants and Toddlers (age<2 years old; n=2) | 3.2 ± 17.7 |
| Children (age>=2 and <12 years old; n=36) | 6.7 ± 95.0 |
| Adolescents (age>=12 and <18 years old; n=22) | 4.2 ± 67.6 |
| Above 18 Years (n=1) | 2.4 ± NA |
| Total (n=61) | 5.4 ± 97.1 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
| ng/mL | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age>2yr; n=0; n=0; n=1; n=1) | NA ± NA | NA ± NA | 30.6 ± NA | 53.8 ± NA |
| Children (age>=2 & <12yr; n=11; n=16; n=9; n=7) | 110.6 ± 61.8 | 142.5 ± 80.2 | 111.2 ± 82.6 | 208.4 ± 78.5 |
| Adolescents (age>=12; n=9; n=8; n=9; n=2) | 92.6 ± 50.6 | 116.5 ± 73.0 | 235.1 ± 59.0 | 123.3 ± 68.3 |
| Above 18 years (n=0; n=1; n=0; n=0) | NA ± NA | 143.2 ± NA | NA ± NA | NA ± NA |
| Total | 102.1 ± 58.0 | 133.6 ± 77.6 | 148.1 ± 75.0 | 163.9 ± 87.6 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hour | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1) | NA ± NA | NA (NA to NA) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) |
| Children (age>=2 & <12yr; n=11; n=16; n=9; n=7) | 1.1 ± 61.8 | 1.5 (0.5 to 3.2) | 1.1 (0.6 to 4.1) | 1.0 (0.9 to 2.2) |
| Adolescents (age>=12 & <12yr; n=9; n=8; n=9; n=2) | 1.0 (0.5 to 4.0) | 1.1 (0.5 to 4.0) | 1.0 (0.5 to 6.0) | 1.6 (1.0 to 2.1) |
| Above 18 years (n=0; n=1; n=0; n=0) | NA (NA to NA) | 0.9 (0.9 to 0.9) | NA (NA to NA) | NA (NA to NA) |
| Total | 1.0 (0.5 to 4.0) | 1.1 (0.5 to 4.0) | 1.0 (0.5 to 6.0) | 1.0 (0.5 to 2.2) |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration.
| ng.h/mL | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1) | NA ± NA | NA ± NA | 100.8 ± NA | 134.9 ± NA |
| Children (age>=2 & <12yr; n=10; n=16; n=8; n=6) | 295.0 ± 63.5 | 490.8 ± 96.7 | 373.5 ± 82.0 | 676.7 ± 99.9 |
| Adolescents (age>=12 & <18yr; n=9; n=8; n=9; n=2) | 320.8 ± 59.1 | 488.1 ± 35.0 | 787.0 ± 76.2 | 526.1 ± 56.6 |
| Above 18 years (n=0; n=1; n=0; n=0) | NA ± NA | 367.2 ± NA | NA ± NA | NA ± NA |
| Total | 307.0 ± 60.2 | 484.3 ± 88.9 | 504.1 ± 89.6 | 534.9 ± 103.9 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(INF) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
| ng.h/mL | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1) | 0 ± 0 | 0 ± 0 | 127.7 ± NA | 142.1 ± NA |
| Children (age>=2 & <12yr; n=10; n=14; n=7; n=5) | 313.9 ± 59.8 | 513.6 ± 99.2 | 429.1 ± 76.8 | 817.6 ± 93.7 |
| Adolescents (age>=12 & <18yr; n=8; n=5; n=7; n=2) | 305.8 ± 60.9 | 605.1 ± 25.3 | 1008.9 ± 69.4 | 547.8 ± 58.2 |
| Above 18 years (n=0; n=1; n=0; n=0) | 0 ± 0 | 390.0 ± NA | 0 ± 0 | 0 ± 0 |
| Total | 310.3 ± 58.6 | 527.8 ± 90.4 | 589.8 ± 86.2 | 594.4 ± 101.5 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
| hour | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1) | NA ± NA | NA ± NA | 2.5 ± NA | 1.8 ± NA |
| Children (age>=2 & <12yr; n=10; n=14; n=7; n=5) | 2.4 ± 1.0 | 3.9 ± 1.9 | 4.6 ± 3.5 | 3.2 ± 1.9 |
| Adolescents (age>=12 & <18yr; n=8; n=5; n=7; n=2) | 3.7 ± 1.6 | 5.1 ± 0.5 | 4.5 ± 2.5 | 3.5 ± 2.9 |
| Above 18 years (n=0; n=1; n=0; n=0) | NA ± NA | 7.3 ± NA | NA ± NA | NA ± NA |
| Total | 3.0 ± 1.4 | 4.4 ± 1.8 | 4.4 ± 2.9 | 3.1 ± 1.9 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
| ng/mL | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1) | NA ± NA | NA ± NA | NA ± NA | 1.2 ± NA |
| Children (age>=2 & <12yr; n=10; n=16; n=7; n=7) | 3.6 ± 46.4 | 3.4 ± 82.0 | 6.0 ± 69.3 | 4.8 ± 65.3 |
| Adolescents (age>=12 & <18yr; n=8; n=8; n=9; n=2) | 3.1 ± 40.3 | 3.6 ± 56.7 | 6.9 ± 75.0 | 4.3 ± 77.9 |
| Above 18 years (n=0; n=1; n=0; n=0) | NA ± NA | 2.2 ± NA | NA ± NA | NA ± NA |
| Total | 3.4 ± 43.7 | 3.4 ± 74.4 | 6.5 ± 72.0 | 4.1 ± 70.8 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hour | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 0.9 (0.9 to 0.9) |
| Children (age>=2 & <12yr; n=10; n=16; n=7; n=7) | 2.0 (1.0 to 4.5) | 2.0 (0.5 to 6.0) | 2.1 (1.0 to 4.1) | 2.0 (1.0 to 2.2) |
| Adolescents (age>=12 & <18yr ; n=8; n=8; n=9; n=2) | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 8.1) | 2.1 (2.0 to 2.1) |
| Above 18 years (n=0; n=1; n=0; n=0) | NA (NA to NA) | 0.9 (0.9 to 0.9) | NA (NA to NA) | NA (NA to NA) |
| Total | 2.0 (1.0 to 4.5) | 2.0 (0.5 to 6.0) | 2.0 (1.0 to 8.1) | 2.0 (0.9 to 2.2) |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration.
| ng.h/mL | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1) | NA ± NA | NA ± NA | NA ± NA | 1.9 ± NA |
| Children (age>=2 & <12yr; n=7; n=12; n=5; n=6) | 8.8 ± 50.4 | 16.6 ± 145.2 | 25.4 ± 71.1 | 23.6 ± 102.2 |
| Adolescents (age>=12 & <12yr; n=6; n=8; n=9; n=2) | 12.3 ± 38.4 | 13.5 ± 54.4 | 20.0 ± 112.3 | 15.8 ± 105.5 |
| Above 18 years (n=0; n=1; n=0; n=0) | NA ± NA | 6.6 ± NA | NA ± NA | NA ± NA |
| Total | 10.3 ± 44.9 | 14.7 ± 141.1 | 21.8 ± 100.1 | 16.3 ± 110.3 |
Concentration of dasatinib in CSF was assessed only in participants who had lumbar puncture during the treatment. y=years
| ng/mL | Dasatinib 60 mg/m^2 | Dasatinib 80 mg/m^2 | Dasatinib 100 mg/m^2 | Dasatinib 120 mg/m^2 |
|---|---|---|---|---|
| Children (age>=2 & <12 y; n=3, n=9, n=3, n=1) | 1.1 ± 0.2 | 1.5 ± 0.6 | 1.7 ± 0.4 | 3.8 ± NA |
| Adolescents (age>=12 & <18 y; n=1; n=1; n=3; n=0) | 1.1 ± NA | 1.0 ± NA | 2.6 ± 0.6 | NA ± NA |
| Total (Children + Adolescents;n=4; n=10; n=6; n=1) | 1.1 ± 0.1 | 1.4 ± 0.6 | 2.1 ± 0.7 | 3.8 ± NA |
BCR-ABL, also referred to as the Philadelphia chromosome, is formed from the fusion of the BCR gene on chromosome 22 with the ABL gene on chromosome 9.
| participants | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| L384M | 1 | 0 |
| G250E | 1 | 0 |
| T315I | 0 | 1 |
| Y253H | 0 | 1 |
| Y253F | 0 | 1 |
| No Mutation | 15 | 11 |
| No Data | 0 | 3 |
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. White Blood Cell (WBC):GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3=\<2.0-1.0\*10\^9/L; GR4=\<1.0\*10\^9/L. Absolute Neutrophil Count (ANC): GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3=\<1.0-0.5\*10\^9/L; GR4=\<0.5\*10\^9/L. Hemoglobin: GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3=\<8.0-6.5g/dL; GR4=\<6.5g/dL. Platelets: GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3=\<50.0-25.0\*10\^9/L; GR4=\<25.0\*10\^9/L. LLN=lower limit of normal.
| participants | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| WBC GR1 | 1 | 2 | 3 |
| WBC GR2 | 0 | 2 | 2 |
| WBC GR3 | 0 | 0 | 6 |
| WBC GR4 | 0 | 1 | 4 |
| ANC GR1 | 1 | 2 | 3 |
| ANC GR2 | 1 | 1 | 0 |
| ANC GR3 | 0 | 2 | 3 |
| ANC GR4 | 0 | 2 | 13 |
| Platelet GR1 | 1 | 5 | 5 |
| Platelet GR2 | 0 | 2 | 3 |
| Platelet GR3 | 0 | 3 | 8 |
| Platelet GR4 | 0 | 2 | 6 |
| Hemoglobin GR1 | 7 | 7 | 7 |
| Hemoglobin GR2 | 1 | 7 | 7 |
| Hemoglobin GR3 | 0 | 1 | 3 |
| Hemoglobin GR4 | 0 | 0 | 0 |
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Aspartate aminotransferase (AST) and alanine aminotransferase(ALT): GR1=\>ULN-2.5\*ULN; GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4=\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN. ULN=upper limit of normal.
| participants | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| AST GR1 | 1 | 3 | 8 |
| AST GR2 | 0 | 2 | 1 |
| AST GR3 | 0 | 1 | 0 |
| AST GR4 | 0 | 0 | 0 |
| AST GR Not Reported | 1 | 3 | 2 |
| High ALT GR1 | 2 | 6 | 6 |
| High ALT GR2 | 0 | 2 | 5 |
| High ALT GR3 | 0 | 0 | 0 |
| High ALT GR4 | 0 | 0 | 0 |
| High ALT GR Not Reported | 0 | 0 | 0 |
| High Total Bilirubin GR1 | 3 | 0 | 1 |
| High Total Bilirubin GR2 | 0 | 1 | 0 |
| High Total Bilirubin GR3 | 0 | 0 | 0 |
| High Total Bilirubin G4 | 0 | 0 | 0 |
| High Total Bilirubin GR Not Reported | 0 | 0 | 1 |
| High Serum Creatinine GR1 | 2 | 0 | 4 |
| High Serum Creatinine GR2 | 0 | 1 | 0 |
| High Serum Creatinine GR3 | 0 | 0 | 0 |
| High Serum Creatinine GR4 | 0 | 0 | 0 |
| High Serum Creatinine GR Not Reported | 0 | 0 | 1 |
GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Low calcium: GR1=\<LLN-8.0 mg/dL, GR2=\<8.0-7.0 mg/dL, GR3=\<7.0-6.0 mg/dL, GR4=\<6.0 mg/dL; Low magnesium: GR1=\<LLN-1.2 mg/dL, GR2=\<1.2-0.9 mg/dL, GR3=\<0.9-0.7 mg/dL, GR4=\<0.7 mg/dL; Low phosphate: GR1=\<LLN - 2.5 mg/dL, GR2=\<2.5 - 2.0 mg/dL, GR3=\<2.0 - 1.0 mg/dL, GR4=\<1.0 mg/dL.
| participants | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| Low Calcium GR1 | 0 | 0 | 1 |
| Low Calcium GR2 | 0 | 0 | 0 |
| Low Calcium GR3 | 0 | 0 | 0 |
| Low Calcium GR4 | 0 | 0 | 0 |
| Low Calcium GR Not Reported | 0 | 0 | 2 |
| Low Magnesium GR1 | 0 | 6 | 0 |
| Low Magnesium GR2 | 0 | 0 | 0 |
| Low Magnesium GR3 | 0 | 0 | 0 |
| Low Magnesium GR4 | 0 | 0 | 0 |
| Low Magnesium GR Not Reported | 0 | 0 | 2 |
| Low Phosphate GR1 | 0 | 1 | 0 |
| Low Phosphate GR2 | 0 | 0 | 0 |
| Low Phosphate GR3 | 0 | 1 | 0 |
| Low Phosphate GR4 | 0 | 0 | 0 |
| Low Phosphate GR Not Reported | 2 | 0 | 2 |
BCR-ABL = These are fused genes found in participants with this type of leukemia.
| participants | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose |
|---|---|---|
| T315I | 0 | 4 |
| No Mutation | 8 | 9 |
| No Data | 9 | 4 |
FLT3 and KIT = These are fused genes found in participants with this type of leukemia.
| participants | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|
| FLT3 Absent | 20 |
| FLT3 Present | 1 |
| FLT3 No Data | 3 |
| KIT Absent | 21 |
| KIT Present | 0 |
| KIT No Data | 3 |
FLT3 and KIT = These are fused genes found in participants with this type of leukemia.
| participants | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|
| FLT3 Absent | 6 |
| FLT3 Present | 0 |
| FLT3 No Data | 18 |
| KIT Absent | 6 |
| KIT Present | 0 |
| KIT No Data | 18 |
Collected over From first dose to 100 days post last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | — | 8/17 (47.1%) | 16/17 (94.1%) |
| Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | — | 14/17 (82.4%) | 16/17 (94.1%) |
| Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | — | 22/24 (91.7%) | 24/24 (100%) |
| Event | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/17 | 0/17 | 7/24 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/17 | 3/17 | 5/24 |
| PyrexiaGeneral disorders | 1/17 | 3/17 | 4/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/17 | 2/17 | 1/24 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/17 | 2/17 | 1/24 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/17 | 0/17 | 2/24 |
| InfectionInfections and infestations | 1/17 | 0/17 | 2/24 |
| PneumoniaInfections and infestations | 0/17 | 0/17 | 2/24 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/17 | 0/17 | 2/24 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/17 | 0/17 | 2/24 |
| Event | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/17 | 7/17 | 6/24 |
| HeadacheNervous system disorders | 11/17 | 5/17 | 6/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/17 | 5/17 | 2/24 |
| NauseaGastrointestinal disorders | 7/17 | 6/17 | 13/24 |
| Abdominal painGastrointestinal disorders | 9/17 | 2/17 | 3/24 |
| VomitingGastrointestinal disorders | 9/17 | 7/17 | 11/24 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/17 | 5/17 | 2/24 |
| PyrexiaGeneral disorders | 5/17 | 8/17 | 8/24 |
| NasopharyngitisInfections and infestations | 8/17 | 2/17 | 0/24 |
| FatigueGeneral disorders | 7/17 | 4/17 | 4/24 |
| Age, Continuous(years) | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | Total |
|---|---|---|---|---|
| Mean | 12.4 ± 4.1 | 9.7 ± 4.3 | 8.6 ± 5.6 | 10.0 ± 5.0 |
| Age, Customized(Participants) | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | Total |
|---|---|---|---|---|
| < 2 years | 0 | 0 | 2 | 2 |
| Between 2 and 6 years | 2 | 5 | 7 | 14 |
| Between 7 and 11 years | 6 | 5 | 7 | 18 |
| Between 12 and 18 years | 9 | 7 | 7 | 23 |
| > 18 years | 0 | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | Total |
|---|---|---|---|---|
| Female | 6 | 5 | 8 | 19 |
| Male | 11 | 12 | 16 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 17 | 16 | 24 | 57 |
| Race/Ethnicity, Customized(Participants) | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | Total |
|---|---|---|---|---|
| White | 16 | 15 | 21 | 52 |
| Black/African American | 0 | 0 | 1 | 1 |
| Asian | 1 | 1 | 1 | 3 |
| Other | 0 | 1 | 1 | 2 |
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb